MSc, Member of the Board of Directors
Pekka Mattila is a co-founder and CEO of Desentum, a clinical-stage biotech company developing novel immunotherapies to treat allergies. Pekka has extensive experience of managing biotech companies, turning innovation into profitable business and of international transactions in the biotech field.
Prior to founding Desentum, he was the co-founder of a Finnish biotech company Finnzymes and acted as its CEO for 25 years until 2010, when the company was acquired by Thermo Fisher Scientific. In addition to TILT Biotherapeutics, Pekka is currently a board member of Aiforia, Medix Group and Mobidiag.
Pekka holds an MSc. from Helsinki University of Technology in biochemistry, biotechnology and microbiology. In 2020 Pekka joined TILT Biotherapeutics as a board member and will apply his expertise to oversee corporate governance, development and business activities.
MD, PhD, eMBA, Founder & CEO and Chairman of the Board
MSc (Tech), Strategy Advisor, Member of the Board of Directors
Legal Advisor, Member of the Board of Directors
MSc (Pharm), Strategy/Commercial Advisor, Member of the Board of Directors
MSc, Business and Administration, Senior Business Advisor